Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20230577 | 0.87 | MEN1 (0.41) | ADORA2AADORA1ADORA3MEN1ALDH1A1 | |
| SCHEMBL20230576 | 0.86 | MEN1 (0.39) | ADORA2AADORA1ADORA3MEN1ALDH1A1 | |
| SCHEMBL20230701 | 0.81 | MEN1 (0.38) | ADORA2AADORA1ALOX15MEN1ALDH1A1 | |
| SCHEMBL20230621 | 0.81 | MEN1 (0.41) | ADORA2AADORA1ADORA3MEN1ALDH1A1 | |
| SCHEMBL20277283 | 0.81 | HTR2A (0.38) | ADORA2AADORA1ADORA3ALOX15TSHR | |
| SCHEMBL20230578 | 0.81 | MEN1 (0.44) | ADORA2AALOX15TSHRMEN1ALDH1A1 | |
| SCHEMBL24293999 | 0.80 | RARB (0.34) | ADORA2AADORA1ADORA3ALOX15TSHR | |
| SCHEMBL20230619 | 0.79 | MEN1 (0.39) | ADORA2AADORA1ADORA3ALOX15MEN1 | |
| SCHEMBL22871818 | 0.79 | — | — | |
| SCHEMBL25138497 | 0.79 | HTR2A (0.45) | ADORA2AADORA1ADORA3ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180159050-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-06-07 | — | — | US | disclosed |
| US-20180159050-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180159050-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CCNE2, CCNT1 | ADORA2A 4680/4885ADORA1 3711/4885ADORA3 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.